middle.news
How Cleo Diagnostics’ New Biobank Access Could Transform Ovarian Cancer Testing
10:21am on Wednesday 25th of June, 2025 AEST
•
Healthcare
Read Story
How Cleo Diagnostics’ New Biobank Access Could Transform Ovarian Cancer Testing
10:21am on Wednesday 25th of June, 2025 AEST
Key Points
Access granted to U.S. National Cancer Institute's PLCO biobank
Two pivotal studies planned to validate Pre-Surgical and Screening Tests
FDA 510(k) submission strengthened with U.S. population data
Complementary partnership with UKCTOCS biobank enhances global evidence
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cleo Diagnostics (ASX:COV)
OPEN ARTICLE